Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
120
resultados
Última actualización
08/12/2025 [07:00:00]
Resultados 75 a 100 de 120
Resumen de: WO2025225632A1
The purpose of the present invention is to provide an antiviral agent effective against COVID-19. The purpose can be achieved by (1) a polypeptide that contains an amino acid sequence selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, and the amino acid sequence represented by SEQ ID NO: 8, or (2) a polypeptide that has antiviral activity against coronavirus, contains an amino acid sequence in which one amino acid is substituted in the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, or the amino acid sequence represented by SEQ ID NO: 8, said polypeptide having an O-glycoside-linked sugar chain.
Resumen de: EP4641196A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Resumen de: ZA202500860B
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Resumen de: WO2024137381A1
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
Resumen de: EP4640230A1
An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Resumen de: WO2024133564A1
: SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Resumen de: KR20250153936A
본 발명은 페이퍼 멤브레인 기반 현장 진단용 DNA 또는 RNA 추출 키트에 관한 것으로, 측방 유동 분리 방식을 기반으로, 짧은 시간 내에 효율적으로 다양한 종류의 샘플들로부터 DNA 또는 RNA 추출이 가능한 DNA 또는 RNA 추출 디바이스로서, 표적 바이러스 검출을 위한 페이퍼 멤브레인 기반 현장용 DNA 또는 RNA 추출 플랫폼을 제공할 수 있다.
Resumen de: US12453717B1
The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is frovatriptan (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide.
Resumen de: LU601360B1
A Chinese medicine formula for COVID-19, comprising the following raw materials by weight ratio: 25 grams of siraitia grosvenorii flower, 10 grams to 20 grams of ligustrum lucidum, 5 grams to 10 grams of winter mulberry leaves, 8 grams to 15 grams of Chinese mahonia, 5 grams to 10 grams of Dizhu leaves, 5 grams to 10 grams of gardenia jasminoides, 3 grams to 8 grams of astragalus membranaceus, 3 grams to 8 grams of gentiana, 5 grams to 10 grams of ophiopogon japonicus, 2 grams to 6 grams of cassia twig, 3 grams to 8 grams of artemisia argyi leaves, and 10 grams to 15 grams of hairy holly. Based on the in-depth analysis of the pathogenesis characteristics of COVID-19, the invention achieves a comprehensive improvement of the symptoms of the COVID-19 by reasonable compatibility of a variety of Chinese medicinal materials; wherein, the combination of siraitia grosvenorii flower and ligustrum lucidum significantly improves the symptoms of dry throat and cough; winter mulberry leaves and Chinese mahonia can synergistically reduce fever quickly; the invention is suitable for various symptoms such as headache, fever, sore throat, chest tightness, cough (dry cough) caused by the COVID-19; generally, it turns from positive to negative in 3 to 4 days, and it takes 5 days to 8 days to eliminate all the symptoms mentioned hereinabove, depending on the physical condition of each person.
Resumen de: US2025327142A1
Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.
Resumen de: WO2025218020A1
Provided are a SARS-CoV-2 camelid-derived nanobody or an antigen-binding fragment thereof, and a composition thereof and a use thereof. The nanobody has at least 95% homology to SEQ ID NO: 1. Mutation engineering of the multivalent nanobody obtained by screening and purifying provides a method for rapidly generating an efficient virus neutralizing agent, such that viral escape mutants can be effectively controlled.
Resumen de: US2025327038A1
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.
Resumen de: US2025327039A1
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.
Resumen de: US2025326715A1
The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Resumen de: US2025325652A1
Provided are an isolated polypeptide or an antigenic fragment thereof, an antibody binding to the isolated polypeptide or the antigenic fragment thereof, a composition including the isolated polypeptide or the antigenic fragment thereof, and an array including the isolated polypeptide or the antigenic fragment thereof. Further provided a method for detecting the presence of an antibody against SARS-COV-2 in a subject, a method for the prognosis of the subject infected with SARS-COV-2, a method for inducing an immune response against SARS-CoV-2 in a subject, and a method for preventing and/or treating a disease caused by SARS-COV-2 infection in a subject.
Resumen de: US2025325547A1
The present invention relates to a compound represented by formula (I), a salt thereof, a solvate thereof, or a prodrug thereof, and an anti-SARS-CoV-2 drug having the same:wherein R1, R2, and R3 are the same or different, and each of them is a hydrogen atom, a halogen atom, a substituted or unsubstituted C1-6-alkyl group, a substituted or unsubstituted C1-6-alkoxy group, or —N(Ra)(Rb) wherein Ra and Rb are the same or different, and each of them is a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group; or Ra and Rb, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring,R4 is —N(Ra)(Rb) wherein Ra and Rb are the same or different, and each of them is a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group; or Ra and Rb, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring,X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, andthe hydroxyl group in the formula may be substituted with a protecting group.
Resumen de: US2025325672A1
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), particularly the spike protein S1 of SARS-COV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-COV-2 or for providing prophylaxis to a subject at risk of infection of SARS-COV-2.
Resumen de: US2025325653A1
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (ΔPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.
Resumen de: US2025325535A1
This invention provides a novel small-molecule allosteric protease inhibitor, 10-(4-methylphenyl)-7-phenyl-6,7,8,10-tetrahydro-5H-indeno1,2-bquinoline-9,11-dione, which exhibits the highest selectivity index (SI), and shows inhibition against several SARS-CoV-2 variants of concern (VOC) and multiple human coronaviruses including MERS-CoV, SARS-CoV, and HCoV-229E. Not only does it demonstrate antiviral potency against a wide spectrum of coronavirus strains and species, but it also shows drug synergism with nirmatrelvir, which could be used in combination therapy to not only treat coronavirus-caused infections and diseases, but also lower the risk of antiviral resistance.
Resumen de: US2025325648A1
Described herein is a replicative Vesicular stomatitis virus (rVSV) comprising: a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein; and a second Filoviridae glycoprotein comprising a SARS-CoV2 Spike protein peptide inserted into the second Filoviridae glycoprotein, or a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein and a non-functional but immunogenic SARS-CoV2 Spike protein. The Spike protein or Spike protein peptide can be derived from different CoV-2 variants. The rVSV can be used as a Dual Action vaccine for vaccinating individuals simultaneously against both influenza virus and SARS CoV2 virus.
Resumen de: US2025327052A1
The invention relates to recombinant mutated angiotensin converting enzyme 2 (ACE2) comprising one or more amino acid substitutions at amino acid positions T27, F28, K31, H34, Y41 and Q42 which have improved binding affinity to SARS-CoV-1 and/or SARS-CoV-2. It also relates to combinatorial mutant ACE2 comprising T27Y/K31 H/H34A, T27YZ K31 H/H134V and T27Y/K31 Y/H134V and the use of said mutant ACE2 for treating and preventing coronavirus infection.
Resumen de: AU2023395159A1
The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.
Resumen de: US2025319181A1
A pheromonicin against SARS-COV-2. Antibody mimetics, i.e., two 28-residues are designed for the first time by selecting the E protein and M protein of SARS-COV-2, which are relatively conserved and have low probability of mutation, as targets. Pharmacodynamic experiments performed using three SARS-COV-2 strains (the epidemic strain GD108, the South Africa strain SA and the India strain IND) respectively prove that fusion proteins obtained by linking the 28-residues to colicin can provide effective protective efficacy against pulmonary lesions induced by SARS-COV-2, and can be used as drugs for treating and preventing SARS-COV-2.
Resumen de: US2025319160A1
The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.
Nº publicación: AU2024253607A1 16/10/2025
Solicitante:
NOVAVAX INC
NOVAVAX, INC
Resumen de: AU2024253607A1
An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.
BOPI
Sede Electrónica
